Yohimbine: Action as Alpha 2 Antagonist

Yohimbine is an indole alkaloid derived from the bark of the West African yohimbe tree (Pausinystalia yohimbe). It acts as a selective antagonist at the alpha 2 adrenergic receptor and thereby increases noradrenaline release in the central and peripheral nervous system. In Germany, yohimbine was approved as a prescription medication for erectile dysfunction, but was withdrawn from the market due to insufficient efficacy and safety concerns. Currently, there is no authorized marketing status as a pharmaceutical. Nevertheless, yohimbine appears in some dietary supplements, bodybuilding products, and internet commerce, making the substance clinically and toxicologically relevant.

From a pharmacological perspective, yohimbine is an interesting but unsafe active substance. The effects are dose dependent and variable: low doses can moderately increase desire, alertness, and in animal models sexual interest, while higher doses lead to tachycardia, blood pressure elevation, anxiety, and insomnia. These risks are difficult to manage outside medical supervision, which is why self medication or consumption as a dietary supplement is clearly not recommended in Germany.

Mechanism of Action

Yohimbine primarily blocks presynaptic alpha 2 adrenergic receptors. These receptors act physiologically as a negative feedback loop: when noradrenaline is released into the synaptic cleft, it inhibits its own further release via alpha 2 receptors. Yohimbine removes this brake, leading to increased sympathetic activity. Clinically this manifests as tachycardia, blood pressure elevation, increased alertness, occasionally anxiety, and tremor.

In erectile function, yohimbine theoretically works through central and peripheral components. In the central nervous system it promotes noradrenaline release in areas associated with sexual arousal. Peripherally it supports vasodilation of the erectile tissue. Clinical efficacy is however limited and not comparable to modern therapy such as PDE5 inhibitors. Studies in the 1980s and 1990s showed contradictory effects with moderate improvement of psychogenic components.

The half life is approximately 30 to 60 minutes, with metabolism occurring predominantly hepatically. Oral bioavailability is extremely variable at 7 to 80 percent, which clinically results in unpredictable peak effects. This variability is one reason the substance is poorly controllable and why standardized dosing remains difficult outside of research settings.

Indications

• Historically in Germany: erectile dysfunction, particularly the psychogenic form, with limited efficacy
• In veterinary medicine: reversal of sedation with alpha 2 agonists such as xylazine or medetomidine in animals, where it remains established
• Research setting: use in pharmacological studies to characterize adrenergic functions, such as provoking anxiety reactions

There is no regular indication in human medicine in Germany. For erectile dysfunction, PDE5 inhibitors such as sildenafil, tadalafil, and vardenafil are established and well tolerated therapies. When psychological stressors are involved, sexual medicine and psychotherapeutic counseling is appropriate.

Dosage and Administration

In former German approvals: 5 to 10 mg three times daily orally, with individual adjustment. Therapeutic success should be evaluated after several weeks.

In dietary supplements and bodybuilding products: Dosages are often not standardized and vary considerably between products. These applications carry safety risks and are not recommended.

Toxic effects from approximately 30 mg: hypertensive crisis, tachyarrhythmias, panic attacks, seizures. If consumption exceeds safe limits, emergency medical evaluation is required.

In veterinary medicine: dosing per veterinary protocol, weight and species specific.

Renal insufficiency and hepatic insufficiency: due to variable pharmacokinetics and insufficient data, use in these situations is not recommended.

Adverse Effects

Common: tachycardia, blood pressure elevation, sleep disturbances, anxiety, sweating, tremor, nausea.

Occasional: headaches, dizziness, vomiting, dry mouth, rash, chest pain.

Rare but relevant: hypertensive crisis, ventricular arrhythmias, bronchospasm, seizures, manic episodes in predisposed patients, paradoxical sexual dysfunction.

With concomitant antihypertensive or antidepressant medications: clinically relevant interactions up to life threatening reactions are possible.

Toxicologically relevant: toxic doses can be reached even in dietary supplements, especially if yohimbine is not standardized in the declaration. If symptoms such as severe tachycardia, chest pain, or pronounced anxiety occur, immediately call emergency services.

Interactions

• Antihypertensives (beta blockers, ACE inhibitors, ARBs, calcium antagonists, diuretics): contradictory and unpredictable effects, blood pressure elevation despite therapy possible.
• Tricyclic antidepressants and MAO inhibitors: risk for hypertensive crisis and serotonergic or noradrenergic reactions.
• Sympathomimetics (pseudoephedrine, phenylephrine systemic, caffeine, ephedrine): additive sympathomimetic effect, tachycardia and hypertension.
• Stimulants (methylphenidate, amphetamines): significant risk amplification.
• SSRIs and SNRIs: theoretically increased risk for serotonergic reactions, individual assessment.
• Alcohol: unpredictable central effects, combined use not recommended.

Special Information

Pregnancy and breastfeeding: Yohimbine is contraindicated in pregnancy because sympathomimetic effects can stress the uterine circulation and increase the risk of premature delivery. Also not recommended during breastfeeding.

Children and adolescents: no indication in human medicine.

Cardiovascular pre existing disease: in manifest hypertension, coronary heart disease, heart failure, arrhythmia tendency, anxiety disorders, or seizure disorders, yohimbine is dangerous and not recommended.

Kidney and liver: in cases of functional disorders, the unsafe pharmacokinetics are particularly problematic.

Dietary supplements: Products containing yohimbine are offered in online shops or as bodybuilding boosters. The amounts are often not standardized, mixing with other stimulants is possible. Such products should be avoided because the risk of health complications is real.

Erectile dysfunction in Germany: first line today are PDE5 inhibitors such as sildenafil or tadalafil. In case of treatment failure or contraindications, further options such as alprostadil, vacuum devices, penile rings, or surgical procedures come into consideration. Sexual medicine and psychotherapeutic counseling is appropriate because many erectile disturbances have a psychogenic component.

Driving ability: when using yohimbine, reaction capacity is potentially impaired, especially through sleep disturbances and anxiety reactions.

You might also be interested in

• Sildenafil, PDE5 inhibitor as standard therapy for erectile dysfunction
• Tadalafil, long acting PDE5 inhibitor
• Alprostadil, intraurethral or intracavernous in erectile dysfunction
• Clonidine, classical alpha 2 agonist
• Tizanidine, another alpha 2 agonist with different indication profile

Frequently Asked Questions

Sources

• Gelbe Liste, yohimbine active ingredient profile
• BfArM, Federal Institute for Drugs and Medical Devices
• AWMF, guidelines for erectile dysfunction
• German Society for Men's Health